Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Classical hematology 1

Conditions

Ovarian Neoplasms 1Iron Deficiencies 1Carcinoma, Ovarian Epithelial 1Anemia, Iron-Deficiency 1Anemia 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × Ferric Oxide, Saccharated × Clear all
NCT03933813 2023-01-05

Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

University of Wisconsin, Madison

Phase 1/2 Terminated
9 enrolled
Classical hematologyGynecologic

Carcinoma, Ovarian Epithelial, Iron Deficiencies, Anemia, Ovarian Neoplasms, Anemia, Iron-Deficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡